LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre Sells 18,733 Shares of Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 18,733 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $84.77, for a total transaction of $1,587,996.41. Following the transaction, the chief executive officer now owns 1,873,651 shares in the company, valued at approximately $158,829,395.27. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT opened at $84.75 on Wednesday. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58. The business’s 50-day moving average price is $84.27 and its two-hundred day moving average price is $92.91. The company has a market capitalization of $1.91 billion, a P/E ratio of 46.31, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm had revenue of $59.87 million during the quarter, compared to the consensus estimate of $57.61 million. During the same period in the previous year, the firm posted $0.44 EPS. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. On average, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.94%. The ex-dividend date is Thursday, May 15th. LeMaitre Vascular’s dividend payout ratio is 40.40%.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Copeland Capital Management LLC boosted its holdings in LeMaitre Vascular by 0.7% in the fourth quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier’s stock worth $107,990,000 after purchasing an additional 8,623 shares in the last quarter. Congress Asset Management Co. boosted its stake in shares of LeMaitre Vascular by 1.8% during the 4th quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier’s stock worth $66,555,000 after acquiring an additional 13,009 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 1.4% during the 4th quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier’s stock valued at $50,711,000 after acquiring an additional 7,737 shares during the last quarter. Northern Trust Corp raised its stake in shares of LeMaitre Vascular by 5.4% in the 1st quarter. Northern Trust Corp now owns 345,563 shares of the medical instruments supplier’s stock valued at $28,993,000 after acquiring an additional 17,748 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in LeMaitre Vascular by 9.9% in the 1st quarter. Envestnet Asset Management Inc. now owns 285,109 shares of the medical instruments supplier’s stock worth $23,921,000 after purchasing an additional 25,680 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LMAT shares. Oppenheimer cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Lake Street Capital lifted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Finally, Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $98.14.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.